drugset / Trial / NCT01448070

Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers

NCT01448070

Phase 1 Completed 28 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to show that the product of the new production process has a similar pharmacological profile to the traditional process used for the current commercial product Actrapid®.

Timeline

Start
2002-10-15
Primary completion
2002-12-20
Completion
2002-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.2 iu/kg Subcutaneous

Indications